13F Holdings
中文EN

ZOMDF Zomedica Corp.

Pharmaceutical Preparations · OTC · SEC CIK 1684144 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY31.3%
TTM net income YoY81.1%
TTM EPS YoY88.9%
Revenue 3-yr CAGR17.2%
Net income 3-yr CAGR—

Margins

Gross margin64.0%
Operating margin-45.4%
Net margin-41.4%
FCF margin-30.8%
EBITDA margin-40.0%

Returns

ROE-14.3%
ROA-13.0%
ROIC (approx.)-13.3%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets9.3%
Debt / equity0.00x
Current ratio6.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20222021-12-31
Income statement
Revenue$32.03M$27.29M$25.19M$18.93M$4.13M
Cost of revenue$10.35M$8.20M$7.87M$5.46M$1.08M
Gross profit$21.68M$19.09M$17.32M$13.47M$3.05M
R&D expense$7.17M$7.27M$5.74M$2.58M$1.67M
SG&A expense$24.50M$29.66M$29.03M$22.93M$22.75M
Operating income-$84.35M-$51.05M-$43.27M-$21.92M-$21.37M
Interest expense——$175,000$1,000$6,000
Pretax income-$82.14M-$47.54M-$35.86M-$19.38M-$20.72M
Income tax-$278,000-$557,000-$1.33M-$2.37M-$2.33M
Net income-$81.86M-$46.98M-$34.53M-$17.02M-$18.38M
EBITDA-$82.30M-$49.51M-$42.45M-$21.50M-$21.11M
EPS (basic)-0.08-0.05-0.04-0.02-0.05
EPS (diluted)-0.08-0.05-0.04-0.02-0.05
Weighted avg. shares (diluted)979.95M979.95M979.95M979.95M956.53M
Balance sheet
Cash & equivalents$9.02M$7.02M$12.95M$27.40M$194.95M
Receivables$3.01M$2.42M$1.20M$596,000$315,000
Inventory$5.54M$5.06M$5.12M$2.75M$2.85M
Current assets$64.04M$81.77M$99.88M$123.50M$200.41M
PP&E, net$20.91M$24.59M$22.83M$6.81M$1.13M
Goodwill$0$45.56M$61.58M$63.98M$43.29M
Intangibles$38.81M$52.54M$55.36M$41.80M$33.18M
Total assets$127.04M$207.36M$253.20M$279.61M$280.40M
Current liabilities$9.45M$9.33M$9.03M$7.81M$4.34M
Short-term debt————$0
Total liabilities$11.64M$11.70M$13.18M$12.22M$9.51M
Shareholders' equity$115.40M$195.66M$240.02M$267.39M$270.89M
Shares outstanding979.95M979.95M979.95M979.95M979.90M
Cash flow statement
Operating cash flow-$17.65M-$23.63M-$15.97M-$11.67M-$14.28M
Capital expenditure$567,000$5.21M$11.34M$787,000$147,000
Free cash flow-$18.22M-$28.84M-$27.31M-$12.46M-$14.42M
Investing cash flow$19.57M$17.85M$1.58M-$155.88M-$71.92M
Financing cash flow—-$70,000—$8,000$219.16M
Depreciation & amortization$2.06M$1.54M$830,000$426,000$265,000
Stock-based compensation$2.47M$2.78M$6.26M$7.89M$7.09M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.